Rob's VM

Discussion in 'Daiichi-Sankyo' started by anonymous, Feb 17, 2017 at 12:53 PM.

Tags: Add Tags
  1. #1 anonymous, Feb 17, 2017 at 12:53 PM
    anonymous

    anonymous Guest

    Another drug failing to meet Primary End Point. What does this mean for the future of DSI Oncology?
     
    Quote

  2. #2 anonymous, Feb 17, 2017 at 2:19 PM
    anonymous

    anonymous Guest

    Wow, unbelievable, and laughable at this point
     
    Quote
  3. #3 anonymous, Feb 17, 2017 at 3:04 PM
    anonymous

    anonymous Guest

    Seriously ......how does this company stay in business?!!!
     
    Quote
  4. #4 anonymous, Feb 17, 2017 at 9:02 PM
    anonymous

    anonymous Guest

    Self imploding....like watching a train wreck. Idiots.
     
    Quote
  5. #5 anonymous, Feb 17, 2017 at 10:22 PM
    anonymous

    anonymous Guest

    It's actually watching a train wreck over and over and over again. It just keeps happening.
     
    Quote
  6. #6 anonymous, Feb 18, 2017 at 11:59 PM
    anonymous

    anonymous Guest

    The company had one good molecule Omesartan.... all the rest garbage... all the talented reps that got a 7th to market drug to #2.... all GONE.
     
    Quote
Reply to Thread